A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.

Trial Details

NCT ID
NCT06007846
Phase
PHASE2 / PHASE3
Sponsor
Inova Health Care Services
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Namenda
Locations (sample)
  • Fairfax, Virginia, United States|38.84622,-77.30637
  • Falls Church, Virginia, United States|38.88233,-77.17109

Key Eligibility Criteria

  • Age 18 or older.
  • Patients have newly diagnosed and previously untreated, histologically or radiologically confirmed hepatocellular carcinoma with at least one lesio…
  • Patient's cancer must be deemed locally advanced and unresectable as per the consensus of the Inova Multidisciplinary Cancer Care Conference.
  • Patients must have a Child-Pugh cirrhosis score of B7 or greater and deemed not a candidate for aggressive systemic treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →